TriMas
Makes packaging, life-sciences components, and compressed-gas cylinders after the Aerospace divestiture.
Something off on this page? Send us feedback.
Profile
Sells dispensing, closure, flexible-packaging, and life-sciences components through Packaging, plus Norris Cylinder compressed-gas cylinders through Specialty Products. Packaging is the dominant platform, and the business is now a two-segment manufacturer after divesting Aerospace.
Builds dispensing, closure, flexible-packaging, and life-sciences components through TriMas Packaging, alongside compressed-gas cylinders through Norris Cylinder in Specialty Products. Packaging is the dominant platform, while Specialty Products is the smaller industrial cylinder business.
Operates from Bloomfield Hills with a multi-country manufacturing footprint serving consumer packaging, life sciences, and industrial end markets. Execution is framed around customer success, technical expertise, focused innovation, quality, service, continuous improvement, and operational discipline.
Portfolio shape changed materially after the sales of Arrow Engine and TriMas Aerospace. Aerospace is historical context, not a continuing operating segment.
Company facts
Key statistics
Year to date +8.9% · Average volume (30d) 439.5K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | KeyBanc | Target | $45 | $38 | ||
| Aug 13, 2025 | Keybanc | Upgrade | Sector Weight | Overweight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.49 | $0.52 | +5.4% | $178.4M | $174.6M | −2.2% | −3.23% |
| Apr 30, 2026Q1 FY26 | $0.19 | $0.24 | +26.6% | $158.2M | $168.3M | +6.3% | +4.08% |
| Feb 26, 2026Q4 FY25 | $0.41 | $0.40 | −2.4% | $193.0M | $155.5M | −19.4% | +2.84% |
| Oct 28, 2025Q3 FY25 | $0.56 | $0.61 | +8.2% | $262.1M | $269.3M | +2.7% | −2.30% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $152.5M | $274.8M | $269.3M | $155.5M | $168.3M | $174.6M | |
| Gross profit | $31.2M | $65.9M | $62.1M | $32.9M | $35.4M | $35.3M | |
| Operating income | $5.7M | $27.2M | $24.8M | −$5.0M | $11.0M | $10.9M | |
| Net income | $12.4M | $16.7M | $9.3M | $81.7M | $800.8M | $13.4M | |
| Diluted EPS | $0.30 | $0.41 | $0.23 | $2.04 | $21.40 | $0.37 | |
| Gross margin | 20.4% | 24.0% | 23.1% | 21.2% | 21.0% | 20.2% | |
| Operating margin | 3.7% | 9.9% | 9.2% | -3.2% | 6.5% | 6.2% |
Fiscal years (4-quarter sums)FY21 $857.1M · FY22 $883.8M · FY23 $893.6M · FY24 $846.7M · FY25 $852.0M
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $1.24B · Total debt $437.8M · Total assets $2.25B · Shareholders' equity $1.44B
Dividends
Raised for 3 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 6, 2026 | Aug 6 | Aug 13 | $0.04 | |
| May 7, 2026 | May 7 | May 14 | $0.04 | |
| Feb 27, 2026 | Feb 27 | Mar 6 | $0.04 | |
| Nov 6, 2025 | Nov 6 | Nov 13 | $0.04 | |
| Aug 5, 2025 | Aug 5 | Aug 12 | $0.04 | |
| May 6, 2025 | May 6 | May 13 | $0.04 | |
| Feb 28, 2025 | Feb 28 | Mar 7 | $0.04 | |
| Nov 5, 2024 | Nov 5 | Nov 12 | $0.04 |
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 35.83M · Float 29.02M · 81.0% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Shawn Sedaghat · director, 10 percent owner: | 6.05M | 16.90% | Form 4 | Jul 16, 2026 |
| Bank of America Corp /DE/ | 4.16M | 10.20% | 13G | Feb 11, 2026 |
| BlackRock, Inc. | 2.53M | 7.06% | 13F | Aug 7, 2026 |
| Dimensional Fund Advisors LP | 2.26M | 6.31% | 13F | Aug 11, 2026 |
| Fiduciary Management Inc /WI/ | 2.01M | 5.00% | 13G | Feb 20, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Daniel P. Tredwell | director | +64 | $39.63 |
| Jun 30, 2026 | Herbert K. Parker | director | −15,000 | $45.03 |
| May 13, 2026 | Daniel P. Tredwell | director | +62 | $40.58 |
| May 7, 2026 | Jodi F. Robin | officer: General Counsel and Secretary | −2,000 | $41.61 |
| May 5, 2026 | Jodi F. Robin | officer: General Counsel and Secretary | −3,000 | $41.10 |
Peers
- AptarGroup
Direct overlap in dispensing, closures, and pharma delivery systems
- Silgan
Large dispensing and specialty-closures rival across consumer goods
- Amcor
Scale rival in flexible, rigid, healthcare, and closure packaging
- Greif Class A
Industrial drum and container-closure overlap through Tri-Sure
- West Pharmaceutical Services
Life-sciences components and pharma containment overlap
- Worthington Enterprises
Pressure-cylinder overlap in gas storage and transport
- Luxfer
High-pressure gas-cylinder alternative across medical and industrial uses
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TriMas | $39.53 | +0.01% | $1.42B | 1.6 | 20.1 | 1.8 | −36.5% |
| AptarGroup | $132.99 | −0.02% | $8.49B | 24.0 | 22.4 | 2.2 | +6.3% |
| Silgan | $42.10 | −0.02% | $4.45B | 16.6 | 10.8 | 0.7 | +6.8% |
| Amcor | $46.80 | +0.28% | $21.58B | 19.6 | 10.7 | 0.9 | +25.9% |
| Greif Class A | $84.08 | +0.02% | $3.88B | 4.8 | 18.2 | 1.1 | +2.7% |
| West Pharmaceutical Services | $349.58 | +3.61% | $23.75B | 43.2 | 36.5 | 7.1 | +13.9% |
| Worthington Enterprises | $57.32 | +0.02% | $2.80B | 18.0 | 15.4 | 2.0 | +16.9% |
| Luxfer | $17.17 | −0.03% | $459.5M | 59.3 | 13.2 | 1.3 | −8.0% |
| Median | 19.6 | 15.4 | 1.3 | +6.8% |